Background. Vitamin D and its analogues are reported to have renoprotective effects in chronic kidney disease including diabetic nephropathy (DN). Vitamin D 3 is converted to 1,25(OH)D 3 by CYP2R1 and CYP27B1. The biological action of 1,25(OH)D 3 is mediated via its receptor. VDR, CYP27B1 or CYP2R1 gene variants could modify the biological activity of vitamin D 3 . We have conducted the first case-control association study to determine the relationship between polymorphisms in VDR, CYP27B1 and CYP2R1 genes, and the risk of DN in individuals with type 1 diabetes. Methods. Eight VDR single-nucleotide polymorphisms (SNPs) rs10735810 FokI C>T, rs1544410 BsmI G>A, rs7975232 ApaI G>T, rs731236 TaqI T>C, rs4303288 G>T, rs11168275 C>T, rs12721366 G>A and rs2544043 G>C were investigated with CYP27B1 rs4646536 T>C and CYP2R1 rs10741657 G>A. Genotyping was performed using pyrosequencing, Taqman, Sequenom or direct sequencing technologies in 1329 type 1 diabetics (655 nephropaths, 674 non-nephropaths). Results. No significant differences were observed in genotype or allele frequencies between case and control groups for VDR, CYP27B1 or CYP2R1 SNPs, either before or after stratification by recruitment centre or when restricted to patients with end-stage renal disease. A previously identified haplotype block from rs1544410 to rs731236 was confirmed at the 3 -end of VDR. Comparison of haplotype frequencies identified the rare AGT haplotype as significantly protective against DN, 3.1% cases versus 5.8% controls; χ 2 = 11.05, Pc = 0.009 by the permutation test. Conclusions. Our study has identified a rare VDR haplotype that is protective against DN in patients with type 1 diabetes. Replication in a large, independent cohort is required to confirm this finding.
Introduction
Diabetic nephropathy (DN) affects up to 40% of individuals with type 1 diabetes (T1D) and is the leading cause of endstage renal disease (ESRD) worldwide [1] . The management of DN has become a significant economic burden on health care budgets [2] . Patients with DN develop persistent proteinuria associated with hypertension and a progressive decline in renal function. DN is also associated with an increased risk of cardiovascular disease and higher mortality [3] . Data from both family-based and case-control studies have provided epidemiological evidence for a strong genetic susceptibility to DN, but causal genetic variants have not yet been conclusively identified [4] . Pinpointing these genetic risk factors could improve the ability to predict which patients are most at risk of DN and also highlights genes implicated in both known and novel pathophysiological pathways leading to diabetic kidney injury.
The identification of causative genes involved in a complex disease such as DN has been extremely challenging [4] . Currently, single-nucleotide polymorphisms (SNPs) are the gene variants of choice for genetic association studies, as they represent the most common form of variation in the genome, are suited to automated genotyping and may be functional. In this study, we have used linkage disequilibrium (LD) between SNPs to facilitate identification of causal gene variants. LD occurs when alleles at different loci occur together more often than would be expected by chance alone based on their individual allele frequencies within a population [4] . Blocks of SNPs in close LD are separated by regions of high recombination within the human genome. The set of alleles from contiguous SNPs that reside within a single block define a haplotype [5, 6] . Given the LD that exists between SNPs within a block, only a small number of tag SNPs need be genotyped to define all the variation within a block. This greatly reduces study costs by eliminating redundancy in the information provided by the SNPs while maintaining power to detect causal variants [7] . Although the tag SNP itself may not result in a direct codon change, the SNP may well be in LD with another polymorphism that does result in a functional change. Of particular interest are SNPs within the 5 region of a gene, as they may alter transcription factor binding sites, while those located in the 3 UTR may affect mRNA stability and thus give rise to differences in gene expression.
Vitamin D 3 is essential for life and has diverse physiological roles beyond bone mineral metabolism including blood pressure regulation, enhancing brain activity and immune responsiveness [8, 9] . Vitamin D 3 insufficiency or deficiency contributes to a large number of disorders including renal disease, cancers, osteoporosis and autoimmune conditions such as T1D, rheumatoid arthritis and multiple sclerosis (MS) [10, 11] .
Epidemiological evidence suggests that T1D is more prevalent in countries with lower ambient winter ultraviolet light [12] . Indeed, at the time of diagnosis, plasma 25-hydroxyvitamin D (25(OH)D 3 ) levels are lower compared to controls [13] , supporting the theory that vitamin D supplementation in early childhood may offer protection against T1D [14] . Reduced serum levels of 1,25-dihydroxyvitamin D (1,25(OH) 2 D 3 ) occur early in the development of chronic kidney disease (CKD) and are associated with increased renal inflammation [15, 16] . There is an inverse relationship between plasma 25(OH)D 3 levels and risk of ESRD and death in patients with CKD, stages 2-5 [17] .
The hormonal form of vitamin D, 1,25(OH) 2 D 3 , regulates calcium, phosphate and sulphate balance [18] . Observational data suggest that supplementation with oral calcitriol is associated with improved survival in persons with CKD, especially in persons with concomitant diabetes [19] . Vitamin D, 1,25(OH) 2 D 3 , also decreases the transcription of the renin gene and can therefore directly modulate the renin-angiotensin system activity implicated in the development of DN [20] [21] [22] . Vitamin D has a renoprotective role and reduces kidney injury in diabetic mice [21, 23] . Recently, it has been shown that vitamin D, 1,25(OH) 2 D 3 , protects podocytes from undergoing apoptosis and limits the loss of nephrin in the PAN nephropathy rat model [24] . This finding is supported by in vitro experiments demonstrating that 1,25(OH) 2 D 3 increases nephrin expression in cultured podocytes [21] and blocks hyperglycaemia-induced renal injury by blunting NF-κB activation [25] .
Synthesis of vitamin D 3 or cholecalciferol occurs in three steps that are initiated by ultraviolet light exposure to the skin that converts 7-dehydrocholesterol to previtamin D 3 . It is converted to its major circulating form, 25(OH)D 3 in the liver where hepatic hydrolysis is catalysed predominantly by the cytochrome P450 (CYP) enzyme CYP2R1. The third step produces the most active form (1,25(OH) 2 D 3 ) which is catalysed in the kidney by 25-hydroxyvitamin-D 3 -1-alpha-hydroxylase (CYP27B1) [8] . The majority of vitamin D activities are mediated by a high-affinity receptor. The vitamin D receptor (VDR) acts as a ligand-activated transcription factor which regulates a wide variety of biological processes [9, 10] . Inherited polymorphic variation in VDR or the rate-limiting CYP2R1 or CYP27B1 genes could lead to important changes in gene activation, cell proliferation and immune response [11] .
The VDR gene on chromosome 12q12-14 is composed of eight protein-coding exons (exons 2-9) and six untranslated exons (1a-1f) that are alternatively spliced [26] . In 2004, Nejentsev and colleagues reported data on high-resolution analysis of LD and tag SNPs in the vitamin D gene, identifying three LD blocks [27] . The first block was 3 of exon 9, the second contained VDR exons 3-9 and the final block exon 2 and all non-coding exons. Three of the four commonly typed VDR SNPs ApaI G>T (rs7975232), TaqI C>T (rs731236) and BsmI A>G (rs1544410) reside in the second block, while FokI T>C (rs10735810) resides in the third. This variant (rs10735810) that occurs within a transcription start site produces VDR proteins with different structures and affects immune cell behaviour [28] .
There have been conflicting reports concerning the association of VDR SNPs and T1D; however, both meta-analysis [29] and large multi-centre study [30] indicate that common sequence variation of the VDR gene does not play a major role in T1D. Studies examining the effects of VDR polymorphisms in renal disease have been limited. Allele G of the VDR BsmI polymorphism has previously been associated with protection against ESRD in a Brazilian population [31] ; however, no association with BsmI or FokI polymorphisms was found in a small Italian study of DN (n = 27) [32] .
The correlation between polymorphisms within CYP27B1 (rs10877012 C>A, rs4646536 T>C) and CYP2R1 (rs10741657 G>A) genes and altered serum levels of 25(OH)D 3 or mRNA expression have been reported for multiple sclerosis, gestational diabetes and T1D [33] [34] [35] [36] . For the CYP27B1 gene, a significant increase in T1D disease risk has been reported for the common C allele of rs10877012 and common T allele of rs4646536 (which are in perfect LD in a United Kingdom population) from both family-based and case-control studies [37, 38] . In CYP2R1, the G variant of rs10741657 is more often transmitted to T1D-affected offspring and occurs more frequently in cases compared to controls [35] .
We have conducted the first case-control association study to examine the relationship between SNPs in three key genes in the vitamin D pathway, VDR, CYP27B1 and CYP2R1 and risk of DN in individuals with T1D. The four commonly assessed VDR SNPs (rs10735810 FokI C>T, rs1544410 BsmI G>A, rs7975232 ApaI G>T, rs731236 TaqI T>C) have been investigated alongside four VDR SNPs that initially showed evidence of association with T1D (rs4303288 G>T, rs11168275 A>G, rs12721366 G>A, rs2544043 G>C) [27] . The CYP27B1 rs4646536 T>C and CYP2R1 rs10741657 G>A SNPs previously associated with T1D and vitamin D levels were also examined [35, 37] .
Materials and methods

Subjects
Ethical approval for this study was obtained from the appropriate University Research Ethics Committee, and written, informed consent was obtained from all participants at the time of recruitment. The type 1 diabetic participants with (cases) and without (controls) DN were white and had parents and grandparents born in the UK or Ireland. All participants were diagnosed with T1D before 35 years of age and required insulin from the time of diagnosis. Cases and controls were derived from the Warren 3 (http://www.diabetes.org.uk/en/About_us/News_Landing_Page/2865/) and the Genetics of Kidneys in Diabetes (GoKinD; http://www.gokind.org) collections recruited from seven centres in the UK (Belfast, Birmingham, Edinburgh, London, Manchester, Newcastle and Plymouth), as well as additional cases and controls from both the Belfast centre and a single centre (Dublin) in the Republic of Ireland.
Cases had diabetes for at least 10 years prior to the onset of persistent proteinuria (>0.5 g/24 h), had diabetic retinopathy and exhibited no clinical, serological or radiological evidence of non-diabetic renal disease. The controls had diabetes for more than 15 years and had no evidence of microalbuminuria on repeat testing. Individuals on antihypertensive medication were excluded from the control population. This avoided the possible misclassification of a diabetic individual as having a 'control phenotype' where the use of antihypertensive treatment may have reduced urinary albumin excretion into the normal range.
Genotyping
The rs403288 SNP was genotyped by pyrosequency using a PSQ TM HS 96A instrument (Biotage, Uppsala, Sweden). Pyrosequencing reactions were preformed according to the manufacturer's instructions. Primer sequences are available on request. Genotyping for VDR rs10735810, rs11168275, rs12721366, rs1544410 and rs731236 SNPs were performed using the Sequenom R MassARRAY iPLEX platform TM (Sequenom, Hamburg, Germany) according to the manufacturer's instructions (www.sequenom.com). A 595 bp fragment of VDR incorporating the SNP rs2544043 was amplified by PCR using HotStar Taq DNA polymerase (Qiagen, Crawley, UK) and genotyped by sequencing on an ABI 3730 Genetic Analyzer (Applied Biosystems, Warrington, UK) using BigDye R terminator v3.1 cycle sequencing kits (Applied Biosystems, Warrington, UK) according to the manufacturer's instructions.
All subjects were genotyped for SNPs VDR rs7975232, CYP27B1 rs4646536 and CYP2R1 rs10741657 using Taqman 5 -nuclease assays (C_28977635_10, C_25623453_10, C_2958430_10, respectively) on an ABI Prism 7900 Sequence Detection System (Applied Biosystems, Warrington, UK).
Stringent quality control measures were employed for all assays which included combining cases and controls on the same plate, negative controls, sample duplicates, DNAs of known genotype and father-motherproband trios used to assess apparent Mendelian errors. Genotypes were scored independently by two trained personnel. Genotypes were also confirmed in a subset of samples (n = 96) for each SNP by sequencing on an ABI 3730 GA.
Statistical analysis
Genotype frequencies were assessed for Hardy-Weinberg equilibrium (HWE) using a χ 2 goodness-of-fit test with the level of significance set to P < 0.01. Deviation from HWE can occur due to inbreeding, population stratification or inbreeding and if not detected can produce a false positive association in an SNP under investigation [5, 39] . The χ 2 test for contingency tables was used to compare genotype and allele frequencies between case and control subjects with the level of significance set to P < 0.05. Population stratification is the presence of a systematic difference in allele frequencies between subpopulations in a population possibly due to different ancestry. It can be a problem for association studies, such as case-control studies, where the association found could be due to the underlying structure of the population and not a disease-associated locus. Also, the real disease-causing locus might not be found in the study if the locus is less prevalent in the population where the case subjects are chosen. To address this issue, logistic regression was used to perform an analysis that was stratified for recruitment centre (Belfast, Dublin, Birmingham, Newcastle, London, Plymouth, Edinburgh, Manchester). A model assuming that alleles have multiplicative effects was used to derive odds ratios estimating the risk of nephropathy for one allele relative to the other [40] .
LD between SNPs was quantified using Lewontin's D value [41] and haplotype frequencies were estimated using Haploview [42] . The D value is a measure of LD that is scaled to remove allele frequency effects [6] . It indicates the degree to which gametes exhibit maximum potential LD given their allele frequencies and ranges between a value of 0 and 1. The smaller D is the greater the evidence for disruption of ancestral haplotypes [5] . Haplotype blocks were defined using D >0.7. Both single markers and multimarker haplotypes were assessed simultaneously for association with DN using the Haploview permutation test (n = 10 000 repetitions) giving P-values that were corrected for multiple testing. The sample sizes employed in this study were sufficient to give 80% power to detect as significant (P < 0.05 with Bonferroni correction for the 10 markers in the analysis) an odds ratio of 1.8 for a minor allele whose frequency was at least 5% in the control population. Table 1 lists the clinical characteristics of the case and control groups. The age at diagnosis of diabetes was not significantly different between the case and control groups. There were significantly more male cases than controls (54.8% versus 42.2%, P < 0.001), and cases also had a longer duration of diabetes compared to controls (30.0 ± 9.1 year versus 28.6 ± 9.7 year, P = 0.006). As expected, both diastolic and systolic blood pressures were higher in cases versus controls, despite the use of antihypertensive drug treatment by patients with DN (P < 0.001). None of the control subjects were receiving antihypertensive treatment.
Results
Clinical characteristics of patients
Assessment of polymorphisms
A total of 655 cases and 674 controls were genotyped for the VDR and CYP SNPs. All genotype distributions were in HWE except for marker rs11168275 that deviated in the control group (P < 0.001). No significant differences were observed in genotype and allele frequencies between case and control groups for VDR (Table 2) or CYP (Table 3) SNPs. The analysis was also stratified by the recruitment centre (Table 2) , and a subgroup analysis was performed restricting cases to those with ESRD; however, there were no significant differences detected (data not shown). Significant LD was observed between VDR SNPs (Figure 1 ). SNP rs11168276 was omitted from haplotype analysis due to the lack of HWE. Strong LD (D min 0.74) was found in the previously described 3 haplotype block consisting of the rs1544410, rs7975232 and rs731236 markers [29, 43] .
Comparison of haplotype frequencies between case and control groups identified that the rare AGT haplotype occurred less frequently in DN subjects compared to controls (3.1% cases versus 5.8% controls; χ 2 = 11.05, P = 0.0009; Table 4 ). This suggests a significantly protective role of 500 R. J. L. Martin et al. the AGT haplotype against DN with the result remaining significant even after adjustment for multiple testing (Pc = 0.009 by permutation test; Table 4 ). Stratification by gender suggested that the protective effect of the AGT haplotype was present both in male subjects (2.7% cases versus 5.6% controls; χ 2 = 7.13, P = 0.008, Pc = 0.08) and in female subjects (3.7% cases versus 6.0% controls; χ 2 = 3.67, P = 0.05, Pc = 0.45).
Discussion
Vitamin D and its analogues are reported to provide possible renoprotection against DN [20] [21] [22] [23] [24] [25] . We have conducted the first case-control study to examine the relationship between SNPs in three key genes in the vitamin D pathway (VDR, CYP27B1, and CYP2R1) and risk of DN in individuals with T1D. Four commonly examined VDR SNPs (rs10735810 FokI C>T, rs1544410 BsmI G>A, rs7975232 ApaI G>T, rs731236 TaqI T>C) have been assessed together with four SNPs that initially showed evidence of an association with T1D (rs4303288 G>T, rs11168275 A>G, rs12721366 G>A, rs2544043 G>C) [30] . No significant differences were detected in cases versus controls in allele or genotype frequencies for the VDR SNPs examined. Furthermore, within the cases with DN there was no association between allele or genotype frequencies and disease severity (ESRD versus non-ESRD). Allele G of the VDR BsmI polymorphism (rs1544410) has previously been associated with protection against ESRD [31] ; however, no association was found in our study. All allele frequencies detected for the VDR polymorphisms, however, were in agreement with previous studies on T1D (rs4303288 and rs12721366 allele frequencies were reversed in the original publication, S. Nejentsev, personal communication) [30] . CYP27B1 rs4646536 T>C and CYP2R1 rs10741657 G>A SNPs have been previously associated with T1D and vitamin D levels [35, 37] . These SNPs also failed to demonstrate strong association with DN. CYP27B1 rs4646536 T>C allele frequencies were similar to those previously reported in T1D (allele T 67.9% in this study compared to 67.8% previously) [37] ; however, the CYP2R1 rs10741657 G allele frequency (60%) was more in keeping with previously examined healthy controls than T1D patients (allele G 59.5% versus 61.7% healthy controls, 67.3% T1D) [35] .
As previously reported, strong LD was identified between the 3 SNPs of VDR [29, 43] . The rare AGT (BsmI/ApaI/TaqI) haplotype was found to be significantly protective against DN (3.1% cases versus 5.8% controls, Pc = 0.009). Although it has been reported that the risk of developing renal disease in diabetes is greater in men than in women [44] , association with the protective haplotype was evident in both male (2.7% cases versus 5.6% controls, Pc = 0.08) and female T1D suffers (3.7% cases versus 6.0% controls, Pc = 0.45). It must be noted, however, that this haplotype occurs at a low frequency and could be affected by a small number of individuals; therefore, it is important that these findings are replicated to confirm the association. The establishment of 25(OH)D 3 levels, which were not available for these samples, in relation to VDR haplotype would also be of an advantage in future studies.
VDR haplotypes incorporating the three 3 UTR SNPs BsmI/ApaI/TaqI have previously been described with the presence of restriction sites coded as 'b', 'a' and 't' and absence as 'B', 'A' and 'T' (alleles A, T and T, respectively) [43] . The AGT haplotype identified in this study corresponds to 'BaT' and was significantly protective against DN (3.1% cases versus 5.8% controls; χ 2 = 11.05, Pc = 0.009) in our dataset. Interestingly this BaT haplotype is also reported to be protective in Hashimoto's thyroiditis, the most frequent autoimmune thyroid disease with a strong genetic background (1.2% cases versus 6.5% controls, P = 1.3 × 10 −3 ) [45] . This suggested that the haplotype might point to a more generalized protection from autoimmune disease and merits further detailed investigation in other disorders such as multiple sclerosis, rheumatoid arthritis and lupus.
Our study employed stringent quality control procedures, generating >99.9% genotyping success rate in cases and control subjects and 100% concordance between duplicate samples. Strict phenotyping criteria were used in the selection of cases and controls, in order to reduce the possibility of false positive outcomes related to phenotype misclassification. In addition, population stratification was minimized by including only white participants, with parents and grandparents from the UK and Ireland.
The effects of polymorphisms at the 3 -end of VDR on gene expression are currently not fully understood. They may produce differences in translational efficiency of the RNA or indeed may act as markers for disease-causing polymorphisms elsewhere [11] . Differences in VDR mRNA expression level and stability have been identified between 3 VDR haplotypes [46] . Vitamin D is a transcription factor and its receptor regulates transcription of several targeted genes that contain vitamin D response elements (VDRE) within their promoter [47] . The 3 UTR haplotypes of VDR are associated with differential cytokine response in pulmonary tuberculosis [48] , and a major histocompatability complex VDRE has been identified in the promoter of HLA-DRB1 [49] . The latter study suggests a direct functional interaction between vitamin D and the major locus determining genetic susceptibility for MS [49] . The NF-κB subunit relB is also a direct target for 1,25(OH) 2 D 3 -mediated negative transcriptional regulation via VDREs implying a potential immunotherapeutic use for 1,25(OH) 2 D 3 analogues [50] . Further understanding of the cellular and molecular processes influenced by 3 haplotypes of VDR and VDREs in T1D and nephropathy is required to fully appreciate their impact.
In conclusion, we have identified a rare AGT haplotype of VDR that is significantly protective against DN in patients with T1D. Replication in a large, independent cohort is required to confirm this finding.
